Also known as: Clonazepam
Adnil is a benzodiazepine medication that was initially primarily used for the treatment of seizures occurring in epilepsy and for anxiety, specifically anxiety that occurs in panic disorder. Adnil is available in tablet form (0.5 mg, 1 mg, 2 mg) and as disintegrating wafers that are taken orally.
While Adnil is generally prescribed for the treatment of anxiety disorders, such as panic disorder, and seizure control, it is intended as a short-term treatment protocol as opposed to a long-term treatment solution due to issues with tolerance (see below). In addition to treating anxiety and seizures, Adnil has also been used in the treatment of:
chizophrenia, especially when the individual with schizophrenia has a restless or irritable component and is not responding to antipsychotic medications.
The manic phase of bipolar disorder or for restlessness associated with depression in bipolar disorder.
Tic disorders, such as Tourette's syndrome, by acting as a muscle relaxant and producing sedation.
Restless leg syndrome.
Withdrawal from alcohol or treatment for other substance abuse or addiction issues.
Adnil has a relatively slow onset of action (it takes a while for the drug to begin working) and a half-life of between 10 and 50 hours. As it has a relatively slow onset of action and is a longer-acting benzodiazepine, Adnil is more suited for the treatment of anxiety, seizures, and other similar disorders as opposed to being a useful sleep aid, even though it is sometimes prescribed for that purpose. Sleep aids need to work quickly, whereas with Adnil, a person takes the drug early in the day and doesn't have to worry about monitoring for signs of a seizure or panic attack as it stays in the system a relatively long time. Its effects last longer than those of shorter-acting benzodiazepines, such as Xanax.
As it is a Schedule IV controlled substance, Adnil can only be legally acquired with a prescription from a physician.
Your doctor will probably start you on a low dose of Adnil and gradually increase your dose, not more often than once every 3 days.
Adnil can be habit-forming. Do not take a larger dose, take it more often, or take it for a longer period of time or in a different way than prescribed by your doctor. Take Adnil exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Adnil may help control your condition, but will not cure it. It may take a few weeks or longer before you feel the full benefit of Adnil. Continue to take Adnil even if you feel well. Do not stop taking Adnil without talking to your doctor, even if you experience side effects such as unusual changes in behavior or mood, If you suddenly stop taking Adnil, you may experience withdrawal symptoms such as new or worsening seizures, hallucinating (seeing things or hearing voices that do not exist), changes in behavior, sweating, uncontrollable shaking of a part of your body, stomach or muscle cramps, anxiety, or difficulty falling asleep or staying asleep. Your doctor will probably decrease your dose gradually.
Symptoms of clonazepam overdosage, like those produced by other CNS depressants, include somnolence, confusion, coma and diminished reflexes.
Treatment includes monitoring of respiration, pulse and blood pressure, general supportive measures and immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension may be combated by the use of levarterenol or metaraminol. Dialysis is of no known value.
Flumazenil, a specific benzodiazepine-receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for resedation, respiratory depression and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert, including CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, should be consulted prior to use.
Flumazenil is not indicated in patients with epilepsy who have been treated with benzodiazepines. Antagonism of the benzodiazepine effect in such patients may provoke seizures.
Serious sequelae are rare unless other drugs or alcohol have been taken concomitantly.
Tablets should be kept at room temperature, between 15 C and 30 C (59 F and 86 F).